| Autor: |
Gardell, SJ, Hare, TR, Bergum, PW, Cuca, GC, O'Neill-Palladino, L, Zavodny, SM |
| Zdroj: |
Blood; December 1990, Vol. 76 Issue: 12 p2560-2564, 5p |
| Abstrakt: |
The vampire bat salivary plasminogen activator (Bat-PA) is a potent PA that exhibits remarkable selectivity toward fibrin-bound plasminogen (Gardell et al, J Biol Chem 256: 3568, 1989). Herein, we describe the activity of recombinant DNA-derived Bat-PA (rBat-PA) in a human plasma milieu. rBat-PA and recombinant human single-chain tissue plasminogen activator (rt-PA) are similarly efficacious at lysing plasma clots. In stark contrast to rt-PA, the addition of 250 nmol/L rBat-PA to plasma in the absence of a clot failed to deplete plasminogen, alpha 2- antiplasmin and fibrinogen. The lytic activities exhibited by finger- domain minus Bat-PA (F- rBat-PA) and finger and epidermal growth factor- like domains minus Bat-PA (FG- rBat-PA) were less than rBat-PA, especially at low concentrations of PA; nevertheless, these truncated forms also possessed a strict requirement for a fibrin cofactor. The loss of PA activity following the addition of rBat-PA to plasma was slower than that observed when either rt-PA or two-chain rt-PA was added. The efficacy, fibrin selectivity, and decreased susceptibility to inactivation exhibited by rBat-PA in vitro in a human plasma milieu suggests that rBat-PA may be superior to rt-PA for the treatment of thrombotic complications. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
